Atjaunināt sīkdatņu piekrišanu

E-grāmata: Oxidative Stress and Neuroprotection

Edited by , Edited by
Citas grāmatas par šo tēmu:
  • Formāts - PDF+DRM
  • Cena: 213,54 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
  • Šī e-grāmata paredzēta tikai personīgai lietošanai. E-grāmatas nav iespējams atgriezt un nauda par iegādātajām e-grāmatām netiek atmaksāta.
Oxidative Stress and NeuroprotectionPalielināt
Citas grāmatas par šo tēmu:

DRM restrictions

  • Kopēšana (kopēt/ievietot):

    nav atļauts

  • Drukāšana:

    nav atļauts

  • Lietošana:

    Digitālo tiesību pārvaldība (Digital Rights Management (DRM))
    Izdevējs ir piegādājis šo grāmatu šifrētā veidā, kas nozīmē, ka jums ir jāinstalē bezmaksas programmatūra, lai to atbloķētu un lasītu. Lai lasītu šo e-grāmatu, jums ir jāizveido Adobe ID. Vairāk informācijas šeit. E-grāmatu var lasīt un lejupielādēt līdz 6 ierīcēm (vienam lietotājam ar vienu un to pašu Adobe ID).

    Nepieciešamā programmatūra
    Lai lasītu šo e-grāmatu mobilajā ierīcē (tālrunī vai planšetdatorā), jums būs jāinstalē šī bezmaksas lietotne: PocketBook Reader (iOS / Android)

    Lai lejupielādētu un lasītu šo e-grāmatu datorā vai Mac datorā, jums ir nepieciešamid Adobe Digital Editions (šī ir bezmaksas lietotne, kas īpaši izstrādāta e-grāmatām. Tā nav tas pats, kas Adobe Reader, kas, iespējams, jau ir jūsu datorā.)

    Jūs nevarat lasīt šo e-grāmatu, izmantojot Amazon Kindle.

This book deals with basic and clinical aspects of monoamine oxidase (MAO) subtypes A and B highlighting its importance in neurological and psychiatric diseases. Consequently the therapeutic actions of MAO-A and -B inhibitors in Parkinson's disease (PK) and depression are the focus of several chapters. As MAO is the basis of the development of the "oxidative stress hypothesis" of PD, several chapters are devoted to iron and iron-induced oxidative stress in various experimental studies and clinical conditions. Based on these findings, new compounds have been developed which not only block MAO, but are in addition, either inhibitors of acetylcholine esterase or have iron chelating properties. The aspect of "preclinical" and "clinical" neuro protection as well as MAO neuroprotection are additional topics covered in this book. MAO, iron and neuroprotection are seen in the framework of general anti Parkinson's therapy with chapters on levodopa, dopaminergic receptor agonists and clinical issues.
Levodopa in the treatment of Parkinson's disease
1(16)
Fahn, S.
Changing dopamine agonist treatment in Parkinson's disease: experiences with switching to pramipexole
17(10)
Reichmann, H.
Odin, P.
Brecht, H. M.
Koster, J.
Kraus, P. H.
The DONPAD-study -- Treatment of dementia in patients with Parkinson's disease with donepezil
27(4)
Muller, T.
Welnic, J.
Fuchs, G.
Baas, H.
Ebersbach, G.
Reichmann, H.
PD-related psychosis: pathophysiology with therapeutical strategies
31(8)
Wolters, E. Ch.
Antioxidant capacity in postmortem brain tissues of Parkinson's and Alzheimer's diseases
39(6)
Sofic, E.
Sapcanin, A.
Tahirovic, I.
Gavrankapetanovic, I.
Jellinger, K.
Reynolds, G. P.
Tatschner, T.
Riederer, P.
Apoptosis inhibition in T cells triggers the expression of proinflammatory cytokines -- implications for the CNS
45(8)
Scheller, C.
Riederer, P.
Gerlach, M.
Koutsilieri, E.
Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells
53(14)
Nagatsu, T.
Sawada, M.
Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection
67(12)
Naoi, M.
Maruyama, W.
Akao, Y.
Yi, H.
Yamaoka, Y.
The relationship of early studies of monoamine oxidase to present concepts
79(8)
Kopin, I. J.
Isatin, an endogenous MAO inhibitor, and a rat model of Parkinson's disease induced by the Japanese encephalitis virus
87(10)
Minami, M.
Hamaue, N.
Hirafuji, M.
Saito, H.
Hiroshige, T.
Ogata, A.
Tashiro, K.
Parvez, S. H.
Isatin interaction with glyceraldehyde-3-phosphate dehydrogenase, a putative target of neuroprotective drugs: partial agonism with deprenyl
97(8)
Medvedev, A.
Buneeva, O.
Gnedenko, O.
Fedchenko, V.
Medvedeva, M.
Ivanov, Y.
Glover, V.
Sandler, M.
Inhibition of amine oxidases by the histamine-1 receptor antagonist hydroxyzine
105(8)
O'Sullivan, J.
O'Sullivan, M. I.
Tipton, K. F.
Davey, G.
Neuroprotection for Parkinson's disease
113(10)
LeWitt, P. A.
Marker for a preclinical diagnosis of Parkinson's disease as a basis for neuroprotection
123(10)
Berg, D.
Assessing neuroprotection in Parkinson's disease: from the animal models to molecular neuroimaging in vivo
133(10)
Ceravolo, R.
Sgado, P.
Frosini, D.
Corsini, G. U.
Deprenyl: from chemical synthesis to neuroprotection
143(14)
Magyar, K.
Palfi, M.
Jenei, V.
Szoko, E.
The use of rasagiline in Parkinson's disease
157(6)
Schapira, A. H. V.
Novel neuroprotective neurotrophic NAP analogs targeting metal toxicity and oxidative stress: potential candidates for the control of neurodegenerative diseases
163(10)
Zheng, H.
Blat, D.
Fridkin, M.
Acute and chronic effects of developmental iron deficiency on mRNA expression patterns in the brain
173(24)
Clardy, S. L.
Wang, X.
Zhao, W.
Liu, W.
Chase, G. A.
Beard, J. L.
True Felt, B.
Connor, J. R.
Long lasting effects of infancy iron deficiency -- Preliminary results
197(4)
Yehuda, S.
Yehuda, M.
Altered regulation of iron transport and storage in Parkinson's disease
201(4)
Hirsch, E. C.
Iron dyshomeostasis in Parkinson's disease
205(10)
Salazar, J.
Mena, N.
Nunez, M. T.
Cerebral oligemia and iron influence in cerebral structures -- element of Morbus Parkinson Models?
215(14)
Sontag, T. A.
Heim, C.
Kolasiewicz, W.
Horn, J.
Pardowitz, I.
Sontag, K. H.
Impact of selenium, iron, copper and zinc in on/off Parkinson's patients on L-dopa therapy
229(8)
Qureshi, G. A.
Qureshi, A. A.
Memon, S. A.
Parvez, S. H.
Metal specificity of an iron-responsive element in Alzheimer's APP mRNA 5'untranslated region, tolerance of SH-SY5Y and H4 neural cells to desferrioxamine, clioquinol, VK-28, and a piperazine chelator
237(12)
Bandyopadhyay, S.
Huang, X.
Cho, H.-H.
Greig, N.
Youdim, M.
Rogers, J. T.
Green tea catechins as brain-permeable, non toxic iron chelators to ``iron out iron'' from the brain
249(10)
Mandel, S.
Weinreb, O.
Reznichenko, L.
Kalfon, L.
Amit, T.
Index 259


Biežāk uzdotie jautājumi par e-grāmatām Biežāk uzdotie jautājumi par e-grāmatām
Permanent link: https://www.kriso.lv/db/97832113332802e.html
Keywords: